Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 13/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | ULK1 | O75385 | 2/20 | 0.39 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.38 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412925 | 1.00 | MAP4K1 (0.47) | MAP4K1LRRK2PTK2ULK1ULK2 | |
| Hydrochloric Acid SCHEMBL25230570 | 0.99 | MAP4K1 (0.46) | MAP4K1LRRK2PTK2ULK1ULK2 | |
| Hydrochloric Acid SCHEMBL30412709 | 0.99 | MAP4K1 (0.46) | MAP4K1LRRK2PTK2ULK1ULK2 | |
| SCHEMBL30412801 | 0.95 | LRRK2 (0.41) | MAP4K1LRRK2PTK2 | |
| SCHEMBL25222980 | 0.95 | LRRK2 (0.41) | MAP4K1LRRK2PTK2 | |
| SCHEMBL25226866 | 0.93 | MAP4K1 (0.48) | MAP4K1PTK2 | |
| SCHEMBL30412433 | 0.93 | MAP4K1 (0.48) | MAP4K1PTK2 | |
| SCHEMBL25200401 | 0.93 | MAP4K1 (0.48) | MAP4K1LRRK2TNK2MAP4K3 | |
| SCHEMBL30412097 | 0.93 | MAP4K1 (0.48) | MAP4K1LRRK2TNK2MAP4K3 | |
| SCHEMBL25220635 | 0.88 | MAP4K1 (0.46) | MAP4K1PTK2MAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | MAP4K1 182/4885LRRK2 610/4885PTK2 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.